$Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey$
Código QR

Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey

We retrospectively evaluated the use of gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) acute myeloid leukemia (AML) patients. Twenty-one CD33 positive R/R AML patients who received GO as a single agent in 4 hematology centers were included in this study. The median age was 59, and the media...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ayşe Hilal Eroğlu Küçükdiler, İrfan Yavaşoğlu, Cem Selim, Cansu Atmaca Mutlu, Abdullah Karakuş, Mahmut Bakır Koyuncu, Oktay Bilgir, Orhan Ayyıldız, Eyüp Naci Tiftik, Ali Zahit Bolaman
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Gemtuzumab ozogamicin Acute myeloid leukemia Salvage treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/45ce0eecfb3e4771bd9551a8db580cf6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:45ce0eecfb3e4771bd9551a8db580cf6
record_format	dspace
spelling	oai:doaj.org-article:45ce0eecfb3e4771bd9551a8db580cf62021-11-22T04:24:57ZUse of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey2213-048910.1016/j.lrr.2021.100280https://doaj.org/article/45ce0eecfb3e4771bd9551a8db580cf62021-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2213048921000479https://doaj.org/toc/2213-0489We retrospectively evaluated the use of gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) acute myeloid leukemia (AML) patients. Twenty-one CD33 positive R/R AML patients who received GO as a single agent in 4 hematology centers were included in this study. The median age was 59, and the median ECOG performance score was 2. According to cytogenetic analysis, 1 patient had favorable risk, 12 patients with intermediate, and 8 patients with adverse risk. The overall response rate was 52.3%. Partial response was achieved in 3 of 8 patients with adverse risk. 33.3% of patients developed grade 3 anemia. Grade 4 neutropenia and thrombocytopenia were observed in 80% of the patients. One of the patients died due to sinusoidal obstruction syndrome / veno-occlusive disease (SOS / VOD) due to GO side effects. GO may be considered as a good option for salvage therapy in R/R AML patients.Ayşe Hilal Eroğlu Küçükdilerİrfan YavaşoğluCem SelimCansu Atmaca MutluAbdullah KarakuşMahmut Bakır KoyuncuOktay BilgirOrhan AyyıldızEyüp Naci TiftikAli Zahit BolamanElsevierarticleGemtuzumab ozogamicinAcute myeloid leukemiaSalvage treatmentNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLeukemia Research Reports, Vol 16, Iss , Pp 100280- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Gemtuzumab ozogamicin Acute myeloid leukemia Salvage treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Gemtuzumab ozogamicin Acute myeloid leukemia Salvage treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ayşe Hilal Eroğlu Küçükdiler İrfan Yavaşoğlu Cem Selim Cansu Atmaca Mutlu Abdullah Karakuş Mahmut Bakır Koyuncu Oktay Bilgir Orhan Ayyıldız Eyüp Naci Tiftik Ali Zahit Bolaman Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
description	We retrospectively evaluated the use of gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) acute myeloid leukemia (AML) patients. Twenty-one CD33 positive R/R AML patients who received GO as a single agent in 4 hematology centers were included in this study. The median age was 59, and the median ECOG performance score was 2. According to cytogenetic analysis, 1 patient had favorable risk, 12 patients with intermediate, and 8 patients with adverse risk. The overall response rate was 52.3%. Partial response was achieved in 3 of 8 patients with adverse risk. 33.3% of patients developed grade 3 anemia. Grade 4 neutropenia and thrombocytopenia were observed in 80% of the patients. One of the patients died due to sinusoidal obstruction syndrome / veno-occlusive disease (SOS / VOD) due to GO side effects. GO may be considered as a good option for salvage therapy in R/R AML patients.
format	article
author	Ayşe Hilal Eroğlu Küçükdiler İrfan Yavaşoğlu Cem Selim Cansu Atmaca Mutlu Abdullah Karakuş Mahmut Bakır Koyuncu Oktay Bilgir Orhan Ayyıldız Eyüp Naci Tiftik Ali Zahit Bolaman
author_facet	Ayşe Hilal Eroğlu Küçükdiler İrfan Yavaşoğlu Cem Selim Cansu Atmaca Mutlu Abdullah Karakuş Mahmut Bakır Koyuncu Oktay Bilgir Orhan Ayyıldız Eyüp Naci Tiftik Ali Zahit Bolaman
author_sort	Ayşe Hilal Eroğlu Küçükdiler
title	Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
title_short	Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
title_full	Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
title_fullStr	Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
title_full_unstemmed	Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
title_sort	use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: multi-center real life data from turkey
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/45ce0eecfb3e4771bd9551a8db580cf6
work_keys_str_mv	AT aysehilaleroglukucukdiler useofgemtuzumabozogamicininrelapsedrefractoryacutemyeloidleukemiamulticenterreallifedatafromturkey AT irfanyavasoglu useofgemtuzumabozogamicininrelapsedrefractoryacutemyeloidleukemiamulticenterreallifedatafromturkey AT cemselim useofgemtuzumabozogamicininrelapsedrefractoryacutemyeloidleukemiamulticenterreallifedatafromturkey AT cansuatmacamutlu useofgemtuzumabozogamicininrelapsedrefractoryacutemyeloidleukemiamulticenterreallifedatafromturkey AT abdullahkarakus useofgemtuzumabozogamicininrelapsedrefractoryacutemyeloidleukemiamulticenterreallifedatafromturkey AT mahmutbakırkoyuncu useofgemtuzumabozogamicininrelapsedrefractoryacutemyeloidleukemiamulticenterreallifedatafromturkey AT oktaybilgir useofgemtuzumabozogamicininrelapsedrefractoryacutemyeloidleukemiamulticenterreallifedatafromturkey AT orhanayyıldız useofgemtuzumabozogamicininrelapsedrefractoryacutemyeloidleukemiamulticenterreallifedatafromturkey AT eyupnacitiftik useofgemtuzumabozogamicininrelapsedrefractoryacutemyeloidleukemiamulticenterreallifedatafromturkey AT alizahitbolaman useofgemtuzumabozogamicininrelapsedrefractoryacutemyeloidleukemiamulticenterreallifedatafromturkey
_version_	1718418219162664960

Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey

Ejemplares similares